Compare OBK & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBK | AGIO |
|---|---|---|
| Founded | 1912 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2018 | 2013 |
| Metric | OBK | AGIO |
|---|---|---|
| Price | $50.14 | $29.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $46.67 | $38.88 |
| AVG Volume (30 Days) | 101.5K | ★ 803.6K |
| Earning Date | 04-22-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | $26.43 | $76.75 |
| Revenue Next Year | $5.79 | $170.73 |
| P/E Ratio | $55.69 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.13 | $22.24 |
| 52 Week High | $49.72 | $46.00 |
| Indicator | OBK | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 68.02 | 55.27 |
| Support Level | $46.28 | $26.71 |
| Resistance Level | N/A | $29.64 |
| Average True Range (ATR) | 0.97 | 1.43 |
| MACD | 0.21 | 0.14 |
| Stochastic Oscillator | 99.88 | 75.31 |
Origin Bancorp Inc is a financial holding company that provides personalized, relationship banking to businesses, municipalities, and personal clients in the communities it serves. The company offers a broad range of financial services and operates more than 56 locations in Dallas/Fort Worth, East Texas, Houston, North Louisiana, Mississippi, South Alabama, and the Florida Panhandle. It also provides insurance agency products and services through its wholly owned insurance agency subsidiary. The company operates in one business segment, community banking, and is mainly engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.